Cancer Genetics Inc

Cancer Genetics — Q1 2017 Earnings Presentation

16 slides from Cancer Genetics's earnings presentation, May 12, 2017

  1. Slide 1: Cancer Genetics Incorporated: Empowering Personalized Cancer Treatment

    CANCER GENETICS INCORPORATED Empowering Personalized Cancer Treatment webcast link: http://publi

  2. Slide 2: Forward-Looking Statements

    Gi Forward-Looking Statements These slides may contain forward-looking statements within the meaning of es inaes Seoailics Litgtion| Geom Act of 1995. Alll statements pertaining to future financial and/or operating results, research, technology, clinical development and potential opportunities for a

  3. Slide 3: Everything We Do Is Focused on One Key Idea

    —— ee EVERYTHING WE DOISFOCUSED ON 1 KEY IDEA... ...DELIVER INNOVATION & PATIENT VALUE BY PROVIDING THE MOST COMPREHENSIVE CAPABILITIES IN PRECISION MEDICINE FOR ONCOLOGY DIAGNOSTICS.

  4. Slide 4: Revenue & Growth Highlights

    Gi Revenue & Growth Highlights 1ST QUARTER REVENUE ANNUAL REVENUE $27.0M Numbers in $ millions Numbers in $ millions Q12014 § Q12015 = Q12016 §=Q1 2017 2013 2014 2015 2016 Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2017 Eamings Call

  5. Slide 5: Driving Operational Efficiency and a Clear Path to Profitability

    Driving Operational Efficiency and a Clear G Path to Profitability REVENUE & OPERATING EXPENSES ‘Amounts nS riions Pre-Response ‘Requisition $6.5 $6.3 Post Response ‘Acquisition Fully Integrated “Aéquisition =PeRevenue — —®= Operating Expenses 3.2015 42015 Q12016 Q22016 Q32016 42016 Qt 2017 Q1 OPERA

  6. Slide 6: Revenues By Category

    Gi Revenues By Category 53.7M [fj BIOPHARMA SERVICES = CGI is now supporting over 140 clinical trials and studies focused on Solid Tumor and Blood Cancers, including 32 for immuno-oncology indications $3.0M |_| CLINICAL SERVICES + 21% increase in clinical test volume over Q1 2016 due to enhanced por

  7. Slide 7: Q1 2017 Financial Highlights

    Gi Q1 2017 Financial Highlights = Q1 2017 revenues were $7.0 million, a 15” increase over Q1 2016 revenues of $6.1 million. » Revenue from Biopharma Services grew 11%; Clinical Services increased by 20%; and Discovery Services grew 12” in comparable year-over-year first quarter periods. Total operat

  8. Slide 8: Debt Refinancing and Tax Certificate Program

    Gi Debt Refinancing and Tax Certificate Program = Closed a $12 million debt refinancing with Silicon Valley Bank and Partners for Growth, allowing the Company to access ~$7.6 million in additional capital net of paying off $4.4 million term loan with Silicon Valley Bank. The new $12 million debt fac

  9. Slide 9: Q1 2017 Biopharma Highlights

    Q1 2017 Biopharma Highlights = Working with 9 out of the 10 top biopharma companies. » Revenue from biopharma partners and customers increased by 11% to $3.7 million in Q1 2017 as compared to $3.4 million during Q1 2016. + Announced five agreements and contracts with biotech and pharma customers to

  10. Slide 10: Q1 2017 Clinical & Discovery Highlights

    Gi Q1 2017 Clinical & Discovery Highlights « For the first quarter of 2017, clinical services revenue increased 20% over the same period in 2016, from $2.5 million to $3.0 million. * Clinical growth was driven by an increase in clinical test volumes from 6,608 in Q1 2016 to 7,996 in Q1 2017, an incr

  11. Slide 11: Summary Statement of Operations

    Summary Statement of Operations Income Statement Items ¢s in mousanes) Q1 2016 Q4 2016 Q1 2017 Revenue $6,068, 37230 36,965 | Gross Profit $1,965 $2,958 $2,757 Gross Margin (%) 32% 41% 40% Research & Development (R&D) $1,532 $1,161 $1,110 Sales & Marketing (S&M) $1,298 $937 $974 General & Administra

  12. Slide 12: 2017 Biopharma Highlights: Additional Key Metrics

    Gi 2017 Biopharma Highlights: Additional Key Metrics Le TOTAL ACTIVE PROJECTS ACTIVE I/O PROJECTS BOCKINGS 1 BIELINGIRATIO Qt 2016 v. Q1 2017 Q1 2016 v.Q1 eM, (Qt 2016 v..Q1.2017, 150 140 30 15 1.4 ta 41.2 110 103 a = || ‘0 os 10 3 a — 9 an 2016 a1 2017 1 2016 12017 12016 a1 2017 Realized a 36% incr

  13. Slide 13: Actively Engaged in the Expanding Liquid Biopsy Space

    Gi Actively Engaged in the Expanding Liquid Biopsy Space NEW SERVICE OFFERING | NEW SERVICE OFFERING AIMCO DOM Tol eg Lau BBV Neer THI Ss IE ENTIRE CLINICAL Launched CGl’s first breakthrough NGS-based liquid biopsy CARE CONTINUUM A” test, Liquid::Lung-cfDN, + Provides comprehensive coverage of 11 cr

  14. Slide 14: Artificial Intelligence is Transforming Oncology & Clinical Medicine

    Artificial Intelligence (Al) is Transforming Oncology Gi & Clinical Medicine CGl is very focused on transforming and evolving our value proposition as a critical and preferred partner in the oncology ecosystem by leveraging Al-enabled solutions. + Partnering with select companies to improve our clin

  15. Slide 15: 2017 Goals

    2017 Goals w) @ wHereditary Cancer Testing Panels O Multiple Myeloma NGS Panel [Mayo] wo attificial Intelligence Engine to O Develop Genetic Counselor Network Improve Clinical Trial Matchin: p 9 O Expand Hereditary Service Offering WE id Bioph, Part hi AP ANE SP NARMASEARNSTSN PS O Liquid Biopsy for

  16. Slide 16: CGI Headquarters and Office Locations

    CGI Headquarters 201 Route 17 North Rutherford, NJ 07070 Phone: +1 201-528-9200 RUTHERFORD, NJ Research Triangle Park 133 Southcenter Court Morrisville, NC 27569 Phone: +1 919-465-0100 RALEIGH, NC LOS ANGELES, CA 1640 Marengo Street Fourth Floor Los Angeles, CA 90033 Phone: +1 323-224-3900 #3-1-135/

Cancer Genetics — Q1 2017 Earnings Presentation on 6ix